PDCD1 and cancer: Antibodies against immune checkpoints programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1), or cytotoxic T-lymphocyte antigen-4 (CTLA-4), are breakthroughs in cancer immunotherapy.